A 68-year-old male presents to your office for a follow-up visit. His past medical history is significant for a myocardial infarction (five years ago) and he has type 2 diabetes. His current medications include an ACE inhibitor, a statin, aspirin, and metformin. Despite good compliance with his medications and beneficial lifestyle changes, he is not able to achieve his individualized target A1C of 7.5-8%. You decide it would be beneficial to add a second antihyperglycemic agent. Which of the following medications should be avoided due to CVD risk? A.Pioglitazone B. Exenatide C. Rosiglitazone D. Sitaglipitin E. None of the above Follow the link for the answer.

Obesity is a global epidemic that has far-reaching economic and public health implications. Excess body weight is associated with multiple comorbidities including type 2 diabetes (T2DM), hypertension, obstructive sleep apnea (OSA), and cardiovascular disease (CVD). Dysglycemia andOSA share common risk factors such as age and obesity; hence it is not surprising that OSA and glycemic abnormalities often coexist.

Does adding Zetia to a multifaceted drug therapy regimen help improve health outcomes?

A closer look into what’s new according to the WHO shows if more women are at risk for gestational diabetes than thought.

Letting your patients know how long they may survive and how to extend their survival time can get your patients to increase their physical activity or get them to start.

T2D diagnosed within last 6 years may be able to achieve remission if substantial weight loss is achieved.

By Sheri R. Colberg: Exploring the Benefits of Spontaneous Physical Activity

You’ve probably heard about the recent reports revealing just how dangerous it is to be sedentary. Simply sitting for too long at one time is now a recognized health hazard that everyone should be aware of. But if you suffer from diabetes or prediabetes, a sedentary lifestyle is particularly dangerous. Getting regular exercise and movement is one of the most important things you can do to keep your blood glucose under control, maintain a healthy body weight, and reduce your risk of developing complications related to diabetes.

A 59-year-old patient who was diagnosed with type 2 diabetes five years ago presents to your clinic for an appointment. He has a history of hypertension and dyslipidemia, both currently well-controlled with medication. He has been taking metformin and a DPP-4 inhibitor. He tells you he is concerned about a sore on his foot that is taking a long time to heal. At today’s visit, his office A1C is 8.8%. After discussing his options, you decide to add basal insulin analogue detemir to his regimen. Compared to insulin NPH, what would you expect him to experience while taking detemir? A. Less weight gain B. More hypoglycemia C. More weight gain D. No weight gain or hypoglycemia difference Follow the link for the answer.

Woman, 67 years of age, type 2 diabetes for 22 years, class II obesity. Has recently been managing her glucose levels with weight loss, using Tresiba, Trulicity, and metformin. Recent A1C 6.5%, which she’s worked hard for and been extremely proud of. She hasn’t had numbers like she has recently had for years.

Dyslipidemia: The relationship between cholesterol and cancer risk has been difficult to discern from epidemiologic studies. Individuals with the metabolic syndrome and T2DM frequently have a dyslipidemic profile with elevated triglycerides and decreased high-density lipoprotein cholesterol (HDL-C). In the Metabolic Syndrome Cancer (Me-Can) European cohort elevated triglyceride levels were associated with colon, respiratory, kidney, thyroid cancers, and melanoma in men and respiratory, cervical, and nonmelanoma skin cancers in women.